Nxera Pharma Secures Exclusive Rights to Lucerastat in Japan and Asia Pacific

Nxera Pharma secured exclusive rights to the Phase 3 oral Fabry disease therapy candidate lucerastat for Japan and selected Asia Pacific markets.